Your browser is no longer supported. Please, upgrade your browser.
Settings
PRAH [NASD]
PRA Health Sciences, Inc.
Index- P/E51.37 EPS (ttm)3.27 Insider Own0.30% Shs Outstand64.80M Perf Week-0.99%
Market Cap11.03B Forward P/E24.64 EPS next Y6.81 Insider Trans-80.58% Shs Float64.61M Perf Month-3.04%
Income213.30M PEG3.38 EPS next Q1.45 Inst Own97.20% Short Float4.55% Perf Quarter13.37%
Sales3.33B P/S3.31 EPS this Y-17.40% Inst Trans-2.12% Short Ratio3.99 Perf Half Y37.54%
Book/sh24.26 P/B6.92 EPS next Y12.99% ROA5.30% Target Price167.75 Perf Year77.16%
Cash/sh10.51 P/C15.97 EPS next 5Y15.20% ROE15.40% 52W Range90.79 - 175.95 Perf YTD33.80%
Dividend- P/FCF22.29 EPS past 5Y18.70% ROI9.60% 52W High-4.61% Beta1.32
Dividend %- Quick Ratio1.20 Sales past 5Y14.60% Gross Margin27.10% 52W Low84.87% ATR2.22
Employees18100 Current Ratio1.20 Sales Q/Q19.20% Oper. Margin10.00% RSI (14)47.41 Volatility1.37% 1.29%
OptionableYes Debt/Eq0.82 EPS Q/Q36.20% Profit Margin6.40% Rel Volume1.85 Prev Close166.56
ShortableYes LT Debt/Eq0.74 Earnings- Payout0.00% Avg Volume735.58K Price167.84
Recom2.90 SMA20-0.76% SMA50-0.40% SMA20025.09% Volume1,346,656 Change0.77%
May-10-21Downgrade Truist Buy → Hold $196 → $175
Mar-08-21Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Aug-10-20Downgrade BofA Securities Buy → Underperform $110 → $100
May-01-20Downgrade William Blair Outperform → Mkt Perform
Apr-13-20Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-20Downgrade Goldman Buy → Neutral $130 → $120
Jan-07-20Initiated Citigroup Neutral $120
Nov-14-19Upgrade Wolfe Research Peer Perform → Outperform
Sep-19-19Initiated Goldman Buy $126
Sep-13-19Upgrade KeyBanc Capital Markets Sector Weight → Overweight
May-03-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Oct-09-18Initiated UBS Neutral
Oct-04-18Initiated Evercore ISI In-line
Jan-24-18Downgrade Mizuho Buy → Neutral $86
Dec-11-17Initiated Barclays Overweight $94
Dec-01-17Reiterated Mizuho Buy $82 → $87
Aug-17-17Initiated Raymond James Outperform $89
Jun-26-17Initiated BofA/Merrill Buy $89
Feb-27-17Upgrade Avondale Mkt Underperform → Mkt Perform
Feb-06-17Upgrade Credit Suisse Neutral → Outperform
Jun-23-21 08:01AM  
Jun-15-21 09:16AM  
Jun-01-21 04:55PM  
09:08AM  
May-28-21 03:13PM  
May-26-21 08:05AM  
07:00AM  
May-20-21 12:00AM  
May-19-21 04:45PM  
May-17-21 09:14AM  
May-13-21 07:15PM  
04:02PM  
May-12-21 10:30AM  
May-06-21 10:53AM  
May-05-21 05:25PM  
May-04-21 01:40PM  
May-03-21 12:50PM  
Apr-30-21 06:31PM  
Apr-29-21 02:00PM  
Apr-28-21 05:25PM  
04:01PM  
11:00AM  
Apr-26-21 08:28AM  
Apr-22-21 12:33PM  
10:12AM  
Apr-21-21 04:02PM  
11:05AM  
Apr-16-21 06:53AM  
Apr-15-21 12:15PM  
Apr-14-21 12:42PM  
11:10AM  
07:53AM  
05:43AM  
Apr-13-21 04:02PM  
Apr-12-21 02:24PM  
Apr-08-21 12:24PM  
Apr-07-21 04:50PM  
04:01PM  
Apr-01-21 05:57PM  
05:18PM  
Mar-31-21 04:17PM  
Mar-29-21 09:15AM  
Mar-26-21 11:31AM  
Mar-25-21 06:00AM  
Mar-24-21 07:00PM  
03:34PM  
Mar-23-21 09:08AM  
Mar-22-21 04:01PM  
Mar-20-21 12:40PM  
Mar-19-21 03:10PM  
Mar-18-21 03:10PM  
Mar-17-21 03:51PM  
Mar-16-21 10:31AM  
Mar-14-21 02:06PM  
Mar-11-21 10:39PM  
Mar-10-21 12:05PM  
Mar-08-21 01:39PM  
Mar-07-21 07:41AM  
Mar-04-21 05:40PM  
05:32PM  
Mar-01-21 11:02PM  
07:32PM  
11:11AM  
08:00AM  
Feb-27-21 01:01AM  
Feb-26-21 03:26PM  
01:33PM  
10:49AM  
06:45AM  
Feb-25-21 09:51PM  
07:19AM  
Feb-24-21 02:44PM  
02:09PM  
01:42PM  
12:09PM  
11:20AM  
10:48AM  
10:43AM  
08:49AM  
07:27AM  
07:25AM  
07:13AM  
06:24AM  
06:12AM  
06:04AM  
06:00AM  
03:20AM  
01:57AM  
Feb-15-21 08:47AM  
Feb-04-21 01:01PM  
Jan-08-21 05:36AM  
Jan-07-21 07:15AM  
Dec-17-20 04:02PM  
Dec-04-20 11:31AM  
Dec-03-20 02:03AM  
Nov-30-20 01:31PM  
Nov-19-20 04:02PM  
Nov-09-20 03:06PM  
Nov-06-20 08:07AM  
Nov-05-20 10:01PM  
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHANNON COLINPresident & CEOJun 17Option Exercise46.63442,24120,621,322496,867Jun 21 05:25 PM
Bonello Michael J.EVP & CFOJun 17Option Exercise87.4152,5514,593,69364,415Jun 21 05:27 PM
Bonello Michael J.EVP & CFOJun 17Sale168.7052,5518,865,14711,864Jun 21 05:27 PM
SHANNON COLINPresident & CEOJun 17Sale168.76442,24174,634,06954,626Jun 21 05:25 PM
SHANNON COLINPresident & CEOJun 16Option Exercise11.7388,0451,032,768142,671Jun 17 08:21 PM
Bonello Michael J.EVP & CFOJun 16Option Exercise81.6117,2161,404,99829,080Jun 17 08:25 PM
Gaenzle Christopher LEVP, CAO & General CounselJun 16Option Exercise100.8814,2781,440,30748,778Jun 17 08:50 PM
Gaenzle Christopher LEVP, CAO & General CounselJun 16Sale166.5214,2782,377,50634,500Jun 17 08:50 PM
Bonello Michael J.EVP & CFOJun 16Sale166.4717,2162,865,88711,864Jun 17 08:25 PM
SHANNON COLINPresident & CEOJun 16Sale166.4988,04514,658,51954,626Jun 17 08:21 PM
SHANNON COLINPresident & CEOJun 15Option Exercise11.73132,9861,559,926197,929Jun 17 08:21 PM
Bonello Michael J.EVP & CFOJun 15Option Exercise77.7721,1231,642,64842,990Jun 17 08:25 PM
Gaenzle Christopher LEVP, CAO & General CounselJun 15Option Exercise100.8812,6151,272,55049,088Jun 17 08:50 PM
Gaenzle Christopher LEVP, CAO & General CounselJun 15Sale168.2814,5882,454,83634,500Jun 17 08:50 PM
Bonello Michael J.EVP & CFOJun 15Sale168.2831,1265,238,02111,864Jun 17 08:25 PM
SHANNON COLINPresident & CEOJun 15Sale168.30143,30324,118,43954,626Jun 17 08:21 PM
Bonello Michael J.EVP & CFOJun 01Sale170.452,184372,26321,867Jun 03 04:03 PM
SHANNON COLINPresident & CEOJun 01Sale170.456,4701,102,81264,943Jun 03 04:04 PM
Gaenzle Christopher LEVP, CAO & General CounselJun 01Sale170.45850144,88236,473Jun 03 04:02 PM
Bonello Michael J.EVP & CFOApr 26Sale166.772,048341,54519,228Apr 28 04:17 PM
Gaenzle Christopher LEVP, CAO & General CounselJan 08Sale130.043,136407,80534,500Jan 11 04:26 PM
Bonello Michael J.EVP & CFODec 17Option Exercise11.7333,372391,45454,648Dec 18 04:15 PM
Bonello Michael J.EVP & CFODec 17Sale120.1233,3724,008,64521,276Dec 18 04:15 PM
SHANNON COLINPresident & CEOAug 13Sale102.886,073624,79056,927Aug 17 04:18 PM
Bonello Michael J.EVP & CFOAug 13Sale102.882,052211,11021,276Aug 17 04:17 PM
Gaenzle Christopher LEVP, CAO & General CounselAug 13Sale102.881,364140,32837,636Aug 17 04:17 PM